Neuroprotective effects of metabotropic glutamate receptor ligands in a 6-hydroxydopamine rodent model of Parkinson's disease

European Journal of Neuroscience

Volumn 22, Issue 7, 2005, Pages 1799-1806

  Vernon, A C ^a   Palmer, S ^a   Datla, K P ^a   Zbarsky, V ^a   Croucher, M J ^a   Dexter, D T ^a  

^a CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

6 hydroxydopamine; Excitotoxicity; Glutamate; Metabotropic glutamate receptors; Neuroprotection; Parkinson's disease

Indexed keywords

2 AMINO 4 PHOSPHONOBUTYRIC ACID; 2 METHYL 6 (2 PHENYLVINYL)PYRIDINE; 4 AMINOPYRROLIDINE 2,4 DICARBOXYLATE; 4 CARBOXY 2 METHYLPHENYLGLYCINE; GLUTAMIC ACID; LIGAND; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR AGONIST; METABOTROPIC RECEPTOR ANTAGONIST; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LOSS; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; EXCITOTOXICITY; IN VIVO STUDY; LONG TERM CARE; MALE; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

ANIMALS; BRAIN CHEMISTRY; CELL DEATH; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIAGNOSTIC IMAGING; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; EXCITATORY AMINO ACID ANTAGONISTS; FUNCTIONAL LATERALITY; IMMUNOHISTOCHEMISTRY; LIGANDS; MALE; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE; SUBSTANTIA NIGRA; SYMPATHOLYTICS; TYROSINE 3-MONOOXYGENASE;

EID: 26944465351     PISSN: 0953816X     EISSN: 14609568     Source Type: Journal    
DOI: 10.1111/j.1460-9568.2005.04362.x     Document Type: Article

References (44)

1. Awad, H., Hubert, G.W., Smith, Y., Levey, A.I. & Conn, P.J. (2000) Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J. Neurosci., 20, 7871-7879.
2. Battaglia, G., Busceti, C.L., Pontarelli, F., Biagioni, F., Fornai, F., Paparelli, A., Bruno, V., Ruggieri, S. & Nicoletti, F. (2003) Protective role of group-II metabotropic glutamate receptors against nigro-striatal degeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Neuropharmacology, 45, 155-166.
3. Bradley, S.R., Marino, M.J., Wittmann, M., Rouse, S.T., Awad, H., Levey, A.I. & Conn, P.J. (2000) Activation of Group II metabotropic glutamate receptors inhibits synaptic excitation of the substantia nigra pars reticulata. J. Neurosci., 20, 3085-3094.
4. Breysse, N., Amalric, M. & Salin, P. (2003) Metabotropic glutamate 5 receptor blockade alleviates akinesia by normalizing activity of selective basal-ganglia structures in parkinsonian rats. J. Neurosci., 23, 8302-8309.
5. Breysse, N., Baunez, C., Spooren, W., Gasparini, F. & Amalric, M. (2002) Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. J. Neurosci., 22, 5669-5678.
6. Bruno, V., Battaglia, G., Casabona, G., Copani, A., Caciagli, F. & Nicoletti, F. (1998) Neuroprotection by glial metabotropic glutamate receptors is mediated by transforming growth factor-β. J. Neurosci., 18, 9594-9600.
7. 5 receptors. Neuropharmacology, 38, 199-207.
8. Bruno, V., Sureda, F.X., Storto, M., Casabona, G., Caruso, A., Knopfel, T., Kuhn, R. & Nicoletti, F. (1997) The neuroprotective activity of group-II metabotropic glutamate receptors requires new protein synthesis and involves a glial-neuronal signalling. J. Neurosci., 17, 1891-1897.
9. Carman, L.S., Gage, F.H. & Shults, C.W. (1991) Partial lesion of the substantia nigra: relation between extent of lesion and rotational behaviour. Brain Res., 553, 275-283.
10. Cartmell, J. & Schoepp, D.D. (2000) Regulation of neurotransmitter release by metabotropic glutamate receptors. J. Neurochem., 75, 889-907.
11. Christoffersen, C.L. & Meltzer, L.T. (1995) Evidence for N-methyl-D-aspartate and AMPA subtypes of the glutamate receptor on substantia nigra dopamine neurons: possible preferential role for N-methyl-D-aspartate receptors. Neuroscience, 67, 373-381.
12. 3 metabotropic glutamate receptors enhances the release of nerve growth factor and S-100β protein from cultured astrocytes. Glia, 27, 275-281.
13. Conn, P.J. & Pin, J.-P. (1997) Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol., 37, 205-237.
14. 3 nigrostriatal lesions. Mov. Disord., 16, 424-434.
15. Dexter, D.T., Nanayakkara, I., Goss-sampson, M.A., Muller, D.P.R., Harding, A.E., Marsden, C.D. & Jenner, P. (1994) Nigral dopaminergic cell loss in vitamin E deficient rats. Neuroreport, 5, 1773-1776.
16. Fazal, A., Parker, F., Palmer, A.M. & Croucher, M.J. (2003) Characterisation of the actions of group I metabotropic glutamate receptor subtype selective ligands on excitatory amino acid release and sodium dependant re-uptake in rat cerebrocortical minislices. J. Neurochem., 86, 1346-1358.
17. Kingston, A.E., O'Neill, M.J., Lam, A.G.M., Bales, K.R., Monn, J.A. & Schoepp, D.D. (1999) Neuroprotection by metabotropic receptor agonists: LY354740, LY379268 and LY389795. Eur. J. Pharmacol., 377, 155-165.
18. Kirik, D., Rosenbald, C. & Björklund, A. (1998) Characterization of behavioural and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine. Exp. Neurol., 152, 259-277.
19. Kosiniski, C.M., Standaert, D.G., Testa, C.M., Penny, J.B. & Young, A.B. (1998) Expression of metabotropic glutamate receptor 1 isoforms in the substantia nigra pars compacta of the rat. Neuroscience, 86, 783-798.
20. Kosinski, C.M., Risso, B.S., Conn, P.J., Levey, A.I., Landwehrmeyer, G.B., Penny, J.B., Young, A.B. & Standaert, D.G. (1999) Localisation of metabotropic glutamate receptor 7 mRNA and mGluR7a protein in the rat basal ganglia. J. Comp. Neurol., 415, 266-284.
21. Lafon-Cazal, M., Fagni, L., Guiraud, M.-J., Mary, S., Lerner-Natoli, M. & Pin, J.-P. (1999) mGluR7-like metabotropic glutamate receptors inhibit NMDA-mediated excitotoxicity in cultured mouse cerebellar granule neurons. Eur. J. Neurosci, 11, 663-672.
22. Lee, J.M., Zipfel, G.J. & Choi, D.W. (1999) The changing landscape of ischemic brain injury mechanisms. Nature, 399, A7-A14.
23. MacInnes, M., Messenger, M.J. & Duty, S. (2004) Activation of Group III metabotropic glutamate receptors in selected regions of the basal ganglia alleviates akinesia in the reserpine-treated rat. Br. J. Pharmacol., 141, 15-22.
24. Marek, G. (2004) Metabotropic glutamate 2/3 receptors as drug targets. Curr. Opin. Pharm., 4, 18-22.
25. Matarredona, E.R., Santiago, M., Venero, J.L., Cano, J. & Machado, A. (2001) Group II metabotropic glutamate receptor activation protects striatal dopaminergic nerve terminals against MPP1-induced neurotoxicity along with brain-derived neurotrophic factor induction. J. Neurochem., 76, 351-360.
26. Miranda, A.F., Sutton, M.A., Beninger, R.J., Jhamandas, K. & Boegman, R.J. (1999) Quinolinic acid lesion of nigrostriatal pathways: effect on turning behaviour and protection by elevation of endogenous kynurenic acid in rattus norvegicus. Neurosci. Lett., 262, 81-84.
27. Mitchell, I.J., Clarke, C.E., Boyce, S., Robertson, R.G., Peggs, D., Sambrook, M. A. & Crossman, A.R. (1989) Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridme. Neuroscience, 32, 213-226.
28. Murray, T.K., Messenger, M.J., Ward, M.A., Woodhouse, S., Osbourne, D.J., Duty, S. & O'Niell, M.J. (2002) Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson's disease. Pharmacol, Biochem. Behav., 73, 455-466.
29. Nicoletti, F., Bruno, V., Copani, A., Casabona, G. & Knopfel, T. (1996) Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders? TINS, 1, 267-271.
30. 5 antagonists MPEP and SIB-1893 decrease NMDA or glutamate-mediated neuronal toxicity through actions that reflect NMDA receptor antagonism. Br. J. Pharmacol., 131, 1429-1437.
31. Olanow, C.W. (2002) Surgical therapy for Parkinson's disease. Eur. J. Neurol., 9 (Suppl. 3), 31-39.
32. Ossowska, K., Konieczny, J., Wolfarth, S. & Pile, A. (2005) MTEP a new selective antagonist of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats. Neuropharmacology, 49, 447-455.
33. Ossowska, K., Konieczny, J., Wolfarth, S., Wierónska, J. & Pile, A. (2001) Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats. Neuropharmacology, 41, 413-420.
34. Paxinos, G. & Watson, C. (1986) The Rat Brain in Stereotaxic Co-Ordinates, 2nd Edn. Academic Press, London, UK.
35. Rodriquez, M.C., Obeso, J.A. & Olanow, C.W. (1998) Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann. Neurol., 44, S175-S188.
36. 5 receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine on rotarod, locomotor activity and rotational responses in unilateral 6-OHDA-lesioned rats. Eur. J. Pharmacol., 406, 403-410.
37. Testa, C.M., Friberg, I.K., Weiss, S.W. & Standaert, D.G. (1998) Immunohistochemical localisation of metabotropic glutamate receptors mGluR1a and mGluR2/3 in the rat basal ganglia. J. Comp. Neurol., 390, 5-19.
38. Testa, C.M., Standaert, D.G., Young, A.B. & Penney, J.B. (1994) Metabotropic glutamate receptor mRNA expression in the basal ganglia of the rat. J. Neurosci., 14, 3005-3018.
39. 5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP): complementary in vitro and in vivo evidence. Neuropharmacology, 41, 523-527.
40. Turski, L., Bressler, K., Rettig, K.J., Loschmann, P.A. & Wachtel, H. (1991) Protection of the substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists. Nature, 349, 414-418.
41. Valenti, O., Mannaioni, G., Seabrook, G.R., Conn, P.J. & Marino, M.J. (2005) Group III metabotropic glutamate receptor mediated modulation of excitatory transmission in rodent substantia nigra pars compacta dopamine neurons. J. Pharmacol Exp. Ther., 313, 1296-1304.
42. Wigmore, M.A. & Lacey, M.G. (1998) Metabotropic glutamate receptors depress glutamate-mediated synaptic input to rat midbrain dopamine neurones in vitro. Br. J. Pharmacol., 123, 667-674.
43. Wittmann, M., Marino, M.J. & Conn, P.J. (2002) Dopamine modulates the function of Group II and Group III metabotropic glutamate receptors in the substantia nigra pars reticulata. J. Pharmacol Exp. Ther., 302, 433-441.
44. Yao, H.H., Ding, J.H., Zhou, F., Wang, F., Hu, L.-F., Sun, T. & Hu, G. (2005) Enhancement of glutamate uptake mediates the neuroprotection exerted by activating group II or III metabotropic glutamate receptors on astrocytes. J. Neurochem., 92, 948-961.